No connection

Search Results

ANIK vs HITI

ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%
HITI
High Tide Inc.
BEARISH
Price
$2.33
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ANIK
--
HITI
--
Forward P/E
ANIK
35.5
HITI
16.47
P/B Ratio
ANIK
1.37
HITI
3.23
P/S Ratio
ANIK
1.82
HITI
0.33
EV/EBITDA
ANIK
-29.07
HITI
10.1

Profitability

Gross Margin
ANIK
56.56%
HITI
25.8%
Operating Margin
ANIK
2.11%
HITI
2.32%
Profit Margin
ANIK
-9.64%
HITI
-7.42%
ROE
ANIK
-6.71%
HITI
-39.72%
ROA
ANIK
-3.52%
HITI
3.87%

Growth

Revenue Growth
ANIK
0.0%
HITI
25.2%
Earnings Growth
ANIK
--
HITI
--

Financial Health

Debt/Equity
ANIK
0.18
HITI
1.1
Current Ratio
ANIK
4.72
HITI
1.43
Quick Ratio
ANIK
3.71
HITI
0.49

Dividends

Dividend Yield
ANIK
--
HITI
--
Payout Ratio
ANIK
0.0%
HITI
0.0%

AI Verdict

ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation
HITI BEARISH

HITI exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 25.20% and analysts maintain a 'strong_buy' rating with a target of $5.67, these are contradicted by a 0/100 technical trend and a negative profit margin of -7.42%. The disconnect between analyst optimism and the deterministic health scores suggests a high-risk speculative play rather than a value investment. The company's inability to convert revenue growth into consistent net income remains the primary concern.

Strengths
Strong YoY revenue growth of 25.20%
Positive operating margin of 2.32% suggesting core business viability
Very low Price/Sales ratio (0.33) indicating potential undervaluation of assets
Risks
Critical financial health (Piotroski F-Score 2/9)
Severe technical bearishness (Technical Trend 0/100)
Poor liquidity for immediate obligations (Quick Ratio 0.49)

Compare Another Pair

ANIK vs HITI: Head-to-Head Comparison

This page compares Anika Therapeutics, Inc. (ANIK) and High Tide Inc. (HITI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile